LEAP2 and fatty liver disease: In mice, peripheral and central LEAP2 administration antagonizes orexigenic effects of AG administration, and on its own reduces food intake [36-39], and a long-acting LEAP2 peptide reduces weight hepatic steatosis over four weeks in diet-induced obesity [40].